1-6 of 6
Ross Henderson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Investigating the Therapeutic Potential of the Novel CBP/p300 Protein Degrader CBPD409 in Multiple Myeloma

Stefan Corradini, Saeideh Arsalani, Mina Maksimos, Ebubechukwu Nwarunma, Glen Watt, Richard Soutar, Mathew Powell, Ross Henderson, Zhixiang Chen, Monica L Guzman, Shaomeng Wang, Abdel K Azab, Mark T Williams
Journal: Blood
Blood (2024) 144 (Supplement 1): 5828.
https://doi.org/10.1182/blood-2024-209620
Published: 2024
Journal Articles

Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Jesca Boot, Elizabeth Nelmes, Findlay Bewicke-Copley, Krushika Paleja, Emily Davenport, Ross Henderson, William Hann, Xiao-Yin Zhang, Hannah Bielby, Harshita Goradia, Naim Rahimi, Amjad Hmaid, Rumman Fatima Nizam, Imogen Welding, Vivek Radhakrishnan, Callum Harris, Danielle Monteil, Andrew Clear, Maria Calaminici, Paul Greaves, Andrew J. Davies, Graham P. Collins, Matthew R Wilson, Jeffery Smith, Christopher P Fox, Wendy Osborne, Lucy Cook, Matthew Ahearne, Kate Cwynarski, John G. Gribben, Jessica Okosun
Journal: Blood
Blood (2024) 144 (Supplement 1): 4445.
https://doi.org/10.1182/blood-2024-205820
Published: 2024
Journal Articles

Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma

David Simpson, FRACP, FRCPA, MBChB, James Liang, MBChB, Ross Henderson, MBChB, PhD, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Eileen Merriman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 4049.
https://doi.org/10.1182/blood.V120.21.4049.4049
Published: 2012
Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD
Journal: Blood
Blood (2010) 116 (21): 1961.
https://doi.org/10.1182/blood.V116.21.1961.1961
Published: 2010
Journal Articles

Thalidomide: An Active Agent in AILT Lymphoma

Ross Henderson, David Simpson, MBChB, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Sanjeev Chunilal
Journal: Blood
Blood (2008) 112 (11): 4960.
https://doi.org/10.1182/blood.V112.11.4960.4960
Published: 2008
Journal Articles

Antibodies Targeting Subunit 1 of the N -Methyl-D-Aspartate Receptor May Contribute to Immune Mediated Thrombocytopenia.

Maggie L. Kalev-Zylinska, MD, PhD, FRCPA, Hilary A. Blacklock, Gordon Royle, Ross Henderson, Peter Flanagan, Sharon Jackson, Isuru Dilshan, Wymond Symes, Kathryn Goldstone, Peter Browett, Matthew J. During
Journal: Blood
Blood (2007) 110 (11): 2110.
https://doi.org/10.1182/blood.V110.11.2110.2110
Published: 2007